• citation needed] This systemic therapy (chemotherapy, immunotherapy or hormone therapy) or radiation therapy is commonly used in cancers that are locally advanced, and clinicians plan an operation at a later stage, such as pancreatic cancer. (wikipedia.org)
  • A Meta-analysis of Total Neoadjuvant Therapies Combining Chemoradiotherapy with Induction or Consolidated Chemotherapy for Locally Advanced Rectal Cancer. (bvsalud.org)
  • Total neoadjuvant therapy ( TNT ) combining chemoradiotherapy (CRT) with chemotherapy (CT) was a novel pre-surgical approach to cancer treatment . (bvsalud.org)
  • Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard? (ascopost.com)
  • For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall. (ascopost.com)
  • 1 But the findings of the study were surprising, because neoadjuvant chemotherapy with. (ascopost.com)
  • For patients with advanced non-small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was. (ascopost.com)
  • In general, any patient who is a candidate for adjuvant systemic therapy can be considered for neoadjuvant chemotherapy. (bccancer.bc.ca)
  • In these patients who are poor candidates for resection, a combination of chemotherapy, locoregional therapies like ablation, transarterial chemo and radioembolization, and in very advanced and metastatic disease, external radiation are the available options. (mdpi.com)
  • The present study aimed to investigate the efficacy and safety of sintilimab with chemotherapy (paclitaxel/nab-paclitaxel+platinum or gemcitabine+platinum) in real-world patients with locally advanced or metastatic sqNSCLC. (researchsquare.com)
  • Chabot JA, Wei- Yann T, Fine RL, Chen C, Kumar CK, Antman KA, Grann VR.Pancreatic Proteolytic Enzyme Therapy Compared to Gemcitabine based Chemotherapy For the Treatment of Pancreatic Cancer ( Pancam) J Clin Oncol. (columbiasurgery.org)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • Neoadjuvant chemotherapy (NAC) has become a well-established therapy in the treatment of patients with locally advanced or primarily inoperable breast cancer. (columbia.edu)
  • To investigate the performance of diffusion-weighted (DW) MRI with mono-, bi- and stretched-exponential models in predicting pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) for breast cancer, and further outline a predictive model of pCR combining DW MRI parameters, contrast-enhanced (CE) MRI findings, and/or clinical-pathologic variables. (springer.com)
  • Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. (ac.ir)
  • Distant metastasis has been the main failure pattern for locoregionally advanced rectal cancer (LARC) patients, and intensified neoadjuvant chemotherapy has become a popular research topic. (biomedcentral.com)
  • We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. (jcancer.org)
  • We included 1449 patients with diagnosis of invasive primary breast cancer diagnosed at the MD Anderson Cancer Center between 1995 and 2007 who underwent neoadjuvant chemotherapy. (jcancer.org)
  • No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy. (jcancer.org)
  • Staging of rectal cancer differs from colon cancer in that it is important to assess for locally advanced disease, which is an indication for treatment with chemotherapy and/or radiation prior to surgical intervention. (unina.it)
  • The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. (kjco.org)
  • We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. (kjco.org)
  • 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. (kjco.org)
  • The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression. (kjco.org)
  • In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy. (kjco.org)
  • Neoadjuvant chemotherapy (NC) is a standard therapy for locally advanced breast cancer patients [ 1 ]. (kjco.org)
  • The FDA has granted a priority review to the PD-L1 inhibitor atezolizumab (Tecentriq) for use in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC) as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy. (pharmacytimes.com)
  • Atezolizumab previously received an accelerated approval as a treatment for patients with locally advanced or mUC whose disease progressed during or after platinum-based chemotherapy. (pharmacytimes.com)
  • With regard to chemotherapy, for approximately 80% of patients with locally advanced or metastatic illness, gemcitabine or 5-fluorouracil chemotherapy provides a survival time of months, and nab-paclitaxel combined with gemcitabine or FOLFIRINOX provides slight improvements [ 10 , 11 ]. (hindawi.com)
  • Neoadjuvant chemotherapy has evolved rapidly in recent decades, giving patients with advanced disease more possibilities for surgical resection and radiation therapy [ 12 ]. (hindawi.com)
  • There is a particularly strong need for neoadjuvant chemotherapy trials that will allow the more rapid and less costly efficacy screening of new drugs and drug regimens. (medscape.com)
  • In the past two decades, a multi-therapy approach has increased the rates of clinical response through neoadjuvant chemotherapy, particularly usinga nthracyclines and taxanes-based combination, surgery, radiotherapy and hormone-based therapy 5 . (bvsalud.org)
  • For locally advanced (T3-4/N+M0) rectal cancer (LARC), neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) is the standard treatment. (nih.gov)
  • Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? (wikipedia.org)
  • This meta-analysis aimed to compare the clinical outcomes between neoadjuvant CRT (nCRT) with induction CT and nCRT with consolidated CT in locally advanced rectal cancer (LARC) patients . (bvsalud.org)
  • Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. (uab.cat)
  • Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. (uab.cat)
  • Conclusion: LODDS appears to be a useful prognostic indicator in the prediction of disease-free survival of patients undergoing neoadjuvant chemoradiotherapy and proctectomy for locally advanced rectal cancer. (uab.cat)
  • Currently, neoadjuvant chemo-radiotherapy (nCRT) followed by low anterior resection or abdominoperineal resection are the standard treatments for locally advanced rectal cancer. (sages.org)
  • Although total mesorectal excision is the standard treatment for advanced rectal cancer, recent trends in minimally invasive treatments led to an increase in local excision or "watch and wait" in patients with an excellent response to nCRT. (sages.org)
  • Finally, neoadjuvant therapy consisting of Capecitabine plus radiation therapy, for locally advanced rectal cancer was analysed. (wjgnet.com)
  • Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer. (wustl.edu)
  • Some patients with rectal cancer who achieve a complete response to neoadjuvant chemoradiation therapy can be monitored for tumor recurrence and may never need surgery, according to a retrospective review from patients at Memorial Sloan Kettering Cancer Center, New York, presented at the 2015 Gastrointestinal Cancers Symposium. (ascopost.com)
  • The investigators compared outcomes among 145 patients with stage I to III rectal cancer, 73 of whom achieved a clinical complete response (no detectable tumor by clinical exam, endoscopy, or imaging) after neoadjuvant chemoradiation therapy and were treated nonoperatively. (ascopost.com)
  • Neoadjuvant chemoradiotherapy is recommended to locally advanced rectal cancer, especially for the lower and middle ones. (ac.ir)
  • Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. (ac.ir)
  • Preoperative chemoradiation is now considered standards of care for local advance rectal cancer patients. (unina.it)
  • What is expected for the future in the treatment of rectal cancer is to perform increasingly personalized treatments aimed at improving the complete response to neoadjuvant treatment, without increasing the treatments related toxicity. (unina.it)
  • Deep learning of endoscopic features for assessment of neoadjuvant therapy response in locally advanced rectal cancer. (cdc.gov)
  • INTRODUCTION: The mainstay of management for locally advanced rectal cancer is chemoradiotherapy followed by surgical resection. (lu.se)
  • A population-based study on the management and outcome in patients with locally recurrent rectal cancer. (cancercentrum.se)
  • One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate. (wikipedia.org)
  • 3-6] Most innovative techniques have focused on conformal treatment delivery with computer assisted three-dimensional therapy planning and, in some cases, intensity-modulated radiotherapy in which more complex treatment planning and delivery can allow the radiation oncologist to have better control of doses to healthy tissues. (cancernetwork.com)
  • Radiotherapy dose led to a substantial prolongation of survival in patients with locally advanced rectosigmoid junction cancer: a large population based study. (ac.ir)
  • Triweekly XELOX or capecitabine concurrent with neoadjuvant radiotherapy leads to similar long-term survival outcomes, acute toxicities and surgical complications in LARC patients. (biomedcentral.com)
  • Radiotherapy was delivered to ipsilateral axil- cancer patients in the future, it is essential to increase our lary and supraclavicular lymph nodes and the remaining knowledge in mechanisms responsible for drug resistance, breast parenchyma after breast conservation surgery or tho- and to define reliable indicators for response to therapy. (lu.se)
  • However, the role of neoadjuvant chemoradiotherapy in rectosigmoid junction cancer remains undetermined. (ac.ir)
  • We investigated whether patients with a good response to neoadjuvant chemoradiotherapy will have a relatively better long-term survival compared with those with no response. (ac.ir)
  • All of them had received neoadjuvant chemoradiotherapy and were evaluated by Collaborative Stage Data Collection System. (ac.ir)
  • Response to neoadjuvant chemoradiotherapy and histological type of tumor were the two prognostic factors. (ac.ir)
  • Neoadjuvant therapy aims to reduce the size or extent of the cancer before using radical treatment intervention, thus both making procedures easier and more likely to succeed and reducing the consequences of a more extensive treatment technique, which would be required if the tumor were not reduced in size or extent. (wikipedia.org)
  • The use of therapy can turn a tumor from untreatable to treatable by shrinking the volume. (wikipedia.org)
  • Proton radiation for cancer offers the ability to conform the high-dose region of radiation therapy to the tumor while reducing the dose of radiation to adjacent normal tissues. (cancernetwork.com)
  • Tumor control rates with photon radiation therapy, however, continue to be disappointing, in part because of the dose-limiting constraints associated with these normal structures. (cancernetwork.com)
  • Munich, Germany - September 19, 2023 - Thermosome , a drug development company specializing in targeted tumor therapies, today announced the formation of a Clinical Advisory Board to support the advancement of its lead compound THE001 through clinical development. (wivb.com)
  • Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. (bepress.com)
  • Patients with more than 50% tumor reduction with neoadjuvant therapy had better survival outcomes. (tmu.edu.tw)
  • Some preliminary results show that increasing the duration of therapy to 6 or 8 months further reduces tumor volume and PSA nadir levels and decreases the likelihood of positive margins. (medscape.com)
  • Neoadjuvant immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) is safe and feasible in early-stage non-small cell lung cancer (NSCLC). (ascopost.com)
  • Immunotherapy with an anti-programmed cell death protein 1 (PD-1) inhibitor-pembrolizumab (Keytruda)-showed encouraging responses in patients with advanced cutaneous T-cell lymphoma (either mycosis fungoides or Sézary syndrome). (ascopost.com)
  • Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. (wustl.edu)
  • The use of systemic and or radiation therapy prior to surgery (neoadjuvant therapy or NAT) has been studied since the early 1970s. (bccancer.bc.ca)
  • The neoadjuvant treatment of breast cancer requires a coordinated effort amongst surgical oncology, medical oncology, radiation oncology, nursing, pathology, radiology and clerical booking staff. (bccancer.bc.ca)
  • Proton Radiation Therapy for Lung Cancer: Is There Enough Evidence? (cancernetwork.com)
  • Clinical experience confirms the feasibility of proton radiation for early-stage non-small-cell lung cancers, and clinical trials are being conducted in locally advanced tumors: To date, evidence indicates that proton radiation should be further explored. (cancernetwork.com)
  • Dr. Samson's research interests include multi-modality therapy for malignancies of the lung, esophagus, and mediastinum as well as radiation therapy for cardiac arrhythmias refractory to medical management. (wustl.edu)
  • Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. (wustl.edu)
  • Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer Patients With Higher Positive to Examined Lymph Node Ratio is Associated With Improved Overall Survival. (wustl.edu)
  • Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? (google.fr)
  • Convincing data doexist for the use of adjuvant/neoadjuvant hormonal therapy with external-beam radiation therapy. (cancernetwork.com)
  • Therefore, we focused on the comparison of long-term survival outcomes and the adverse effects of capecitabine plus neoadjuvant radiation with or without triweekly oxaliplatin in LARC patients. (biomedcentral.com)
  • Advances in Radiation Oncology. (elsevierpure.com)
  • However, the NCCN notes that androgen deprivation therapy before, during, and/or after radiation prolongs survival in selected radiation-managed patients. (medscape.com)
  • The mainstay of adjuvant treatment for early-stage, hormone receptor-positive breast cancer has been endocrine therapy, either with tamoxifen and. (ascopost.com)
  • NAT may be considered in certain patients with early stage breast cancer, and is the standard of care for patients with locally advanced breast cancer or inflammatory breast cancer. (bccancer.bc.ca)
  • Stewart suggested that an adaptive clinical trial design, similar to the one employed in the I-SPY 2 neoadjuvant breast cancer trial, can help shift the research away from single-agent studies and "better identify the agents we should be using in kidney cancer. (urologytimes.com)
  • First, I seek to identify breast cancer patients who will not respond to NAC shortly after the initiation of a 5-9 months therapy regimen. (columbia.edu)
  • These findings represent important steps towards the translation of DOT into current clinical workflow to contribute to better-personalized breast cancer therapies and breast cancer risk management. (columbia.edu)
  • Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. (jcancer.org)
  • The study aimed to compare the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone or docetaxel versus ADT alone as neoadjuvant therapy in patients with very-high-risk localized prostate cancer. (frontiersin.org)
  • Compared with ADT alone, neoadjuvant therapy with ADT plus docetaxel or abiraterone could achieve better pathological outcomes (pCR or MRD) for very-high-risk localized prostate cancer. (frontiersin.org)
  • 2015) demonstrated that nivolumab monotherapy, which was used as a second-line therapy compared with docetaxel treatment, remarkably improved treatment efficacy in patients with advanced sqNSCLC. (researchsquare.com)
  • This study demonstrates improved rates of complete pathologic necrosis for patients with HCC who underwent thermal ablation and TARE therapies, when compared to those who received TACE. (arrs.org)
  • Updates of Adjuvant Therapy in Pancreatic Cancer: Where Are We and Where Are We Going? (columbiasurgery.org)
  • The four-year follow-up data is part of the ongoing follow-up study to assess cardiac safety and survival outcome in a subgroup of patients from the Phase 3 study who completed neoadjuvant and adjuvant therapy for one year. (biospace.com)
  • Adjuvant therapy is also further evolving. (hindawi.com)
  • Sintilimab-TP exhibits similar clinical benefits compared with sintilimab-GP in patients with untreated advanced or metastatic sqNSCLC. (researchsquare.com)
  • Prof. Shreyaskumar Patel is a medical oncologist focusing on soft tissue sarcomas (STS), with clinical research interests including systemic therapy for sarcomas, GISTs, and other tumors originating in bone and soft tissues. (wavy.com)
  • Looking ahead, Stewart said there are 11 ongoing neoadjuvant RCC clinical trials listed on ClinicalTrials.gov, comprised of 1 phase 1 trial and 10 phase 2 trials. (urologytimes.com)
  • Here we describe the results from a phase Ib clinical trial (NCT02274155) in which 17 patients with locally advanced head and neck squamous cell carcinoma (HNSCC) received a murine anti-human OX40 agonist antibody (MEDI6469) prior to definitive surgical resection. (bepress.com)
  • Special guest Dr. Zachary Berman, an interventional radiologist who specializes in locoregional therapies for hepatocellular carcinoma, joins us to discuss the implications for clinical practice. (arrs.org)
  • However, neoadjuvant therapy may provide an important paradigm for the discovery of active agents for the treatment of prostate carcinoma, in addition to improving clinical outcomes for men with early, high-risk disease. (medscape.com)
  • 9. Absence of clinical conditions that in the opinion of the investigator, would contraindicate neoadjuvant therapy and/or surgery. (who.int)
  • There is limited evidence to support specific neoadjuvant regimens, but some studies report longer survival with FOLFIRINOX versus gemcitabine plus albumin-bound paclitaxel. (medscape.com)
  • In the area of individual response to cancer treatment, we are integrating germline variation data with biological assessment of innate capacity to repair DNA damage to develop a 'signature' that predicts the magnitude of benefit from chemoradiation therapy. (foxchase.org)
  • Methods: Forty-seven treatment-naive patients with advanced tumors originating from the oral cavity or oropharynx were enrolled. (tmu.edu.tw)
  • 001). Regorafenib is currently approved for the treatment of patients with metastatic colorectal cancer and advanced gastrointestinal stromal tumors. (pharmacytimes.com)
  • Koukourakis GV, Zacharias G, Tsalafoutas J, Theodoridis D, Kouloulias V. Capecitabine for locally advanced and metastatic colorectal cancer: A review. (wjgnet.com)
  • Locoregional therapies for hepatocellular carcinoma perform differently when compared by rates of complete pathologic necrosis of lesions. (arrs.org)
  • Real-life data were collected from patients with untreated locally advanced or metastatic sqNSCLC who were treated with sintilimab plus TP (arm A) or sintilimab plus GP (arm B) between January 2019 and January 2021. (researchsquare.com)
  • Mark G. Kris, MD, discusses neoadjuvant therapy for patients with locally advanced lung cancers. (medscape.com)
  • 1] Non-small-cell lung cancers (NSCLCs) predominate over the small-cell variant of lung cancer, and are usually associated with a poor prognosis, owing to locally advanced or metastatic presentations. (cancernetwork.com)
  • When CRC is discovered at an advanced stage, it can be one of the deadliest and most difficult cancers to tackle. (coloncancerfoundation.org)
  • Prof. Antoine Italiano is an experienced expert in sarcoma and immuno-oncology with a keen interest in translational research aspects related to sensitivity and resistance to targeted therapies, notably in soft-tissue sarcoma models. (wivb.com)
  • Neoadjuvant therapy is the administration of therapeutic agents before a main treatment. (wikipedia.org)
  • The primary endpoint was to determine safety and feasibility of the anti-OX40 neoadjuvant treatment. (bepress.com)
  • We investigated the effect of cetuximab-based sequential therapy as a primary treatment. (tmu.edu.tw)
  • However, this study found something quite different: time from presentation to treatment was not associated with advanced disease or poor survival. (coloncancerfoundation.org)
  • Hormonal treatment of advanced prostate cancer should be consideredfor patients who have stages C and D1 disease, a high risk of recurrenceafter local therapy, or prostate-specific antigen-measured recurrenceafter local treatment. (cancernetwork.com)
  • The neoadjuvant treatment given to the nonoperative patients was not standardized in this retrospective series. (ascopost.com)
  • At the 2022 SUO Annual Meeting, Grant Stewart, MD, PhD, discussed the potential of neoadjuvant therapy as a tool to help optimize the management of patients with localized kidney cancer. (urologytimes.com)
  • I. To determine the recommended phase 2 dose (RP2D) of selinexor in combination with standard-dose pembrolizumab in patients with advanced urothelial carcinoma who are cisplatin-ineligible or platinum-refractory. (bcan.org)
  • To determine the objective response rate (ORR) of selinexor in combination with pembrolizumab in patients with advanced urothelial carcinoma who are cisplatin-ineligible or platinum-refractory. (bcan.org)
  • however, he said that in 2 trials of neoadjuvant nivolumab (Opdivo), "none of the patients had a partial response. (urologytimes.com)
  • Some doctors give the therapy in the hope that a response is seen, and they can then decide what is the best course of action. (wikipedia.org)
  • In some cases, magnetic resonance imaging can predict the response of a patient to neoadjuvant therapy, for example in ovarian cancer. (wikipedia.org)
  • Novel therapies that improve response and long-term efficacy are urgently required. (researchsquare.com)
  • In the open-label, single-arm phase 2 trial, neoadjuvant avelumab/axitinib induced a partial response in 12 (30%) of 40 patients. (urologytimes.com)
  • This would include notonly stage D2 patients, but also menwith stages C and D1 (T3, T4, andany T, N1) disease, a high risk of diseaserecurrence after local therapy, andprostate-specific antigen (PSA) recurrenceafter local therapy. (cancernetwork.com)
  • To further evaluate the efficacy of the combination of selinexor with pembrolizumab in patients with advanced urothelial carcinoma as defined by progression-free survival (PFS). (bcan.org)
  • Current concerns regarding prostate cancer progression have led to a renewed interest in the use of neoadjuvant androgen deprivation (NAD) therapy prior to radical prostatectomy ( RP ). (medscape.com)
  • A total of 132 (96.4%) participants had very-high-risk prostate cancer, and 108 (78.8%) had locally advanced disease. (frontiersin.org)
  • Although hormonal therapy is an importanttreatment modality for advanced prostate cancer, long-termtreatment carries significant side effects that need to be considered. (cancernetwork.com)
  • Although the traditional definitionof 'advanced' prostate cancerencompasses patients with widespreadosteoblastic or soft-tissue metastases,this nomenclature for advanced diseaseshould be challenged. (cancernetwork.com)
  • In addition, despite considerable advances in prostate cancer research, high-risk, localized prostate cancer remains an extremely refractory disease. (medscape.com)
  • As with any therapy, the ultimate benefit of neoadjuvant NAD in prostate cancer will be determined only through properly designed trials with long-term follow-up. (medscape.com)
  • A multidisciplinary approach with a team of oncologists and urologists will be critical to making advances in the arena of neoadjuvant therapy for prostate carcinoma and to aiding in the efficient evaluation of new therapies. (medscape.com)
  • I. To further evaluate the toxicity profile of the combination of selinexor with pembrolizumab in patients with advanced urothelial carcinoma. (bcan.org)
  • The ORIENT-12 study demonstrated the promising results of sintilimab combined with gemcitabine and platinum (GP) therapy in squamous non-small-cell lung cancer (sqNSCLC) patients. (researchsquare.com)
  • 2016). Anti-angiogenesis therapy and targeted therapy can significantly prolong the survival time of non-squamous NSCLC, while they demonstrate moderate benefits for sqNSCLC (Wang and Li 2016). (researchsquare.com)
  • A landmark study showed that the investigational PARP (poly ADP-ribose polymerase) 1/2 inhibitor niraparib, when used as maintenance therapy, significantly improves the outcome of platinum-sensitive recurrent ovarian cancer. (ascopost.com)
  • Diffusion-weighted (DW) MRI, a functional imaging modality which reflects Brownian motion of water molecules in biologic tissues, has been extensively explored for the potential to predict therapy outcome for responders. (springer.com)